Aims: To determine the patterns and predictors of treatment intensification in patients with type 2 diabetes on ≥2 non-insulin antidiabetic drugs (NIADs) and inadequate glycaemic control in primary care in Catalonia, Spain.
| INTRODUCTION
Therapeutic inertia is the failure to initiate or intensify therapy in a well-timed and proper manner in patients who have chronic conditions such as hypertension, dyslipidaemia, or hyperglycaemia 1 or, as most recently stated, failure to close the gap between the most appropriate practice and the patient's usual level of care. 2 In the particular case of type 2 diabetes (T2DM), clinical guidelines for management recommend early and continued adequate glucose control in order to avoid prolonged exposure to hyperglycaemia, which is associated with micro-and macrovascular complications. [3] [4] [5] [6] Nevertheless, over half of patients fail to achieve therapeutic target glycaemic control even with therapy at maximal doses, therefore requiring addition of oral or injectable therapies. [7] [8] [9] The glycated hemoglobin (HbA1c)
value at which treatment intensification is recommended varies between 6.5% and 8.0% in international, 6 ,10-12 national 13 and local 14 guidelines, and it is 8% for incentivization purposes in our institution (Catalan Institute of Health; ICS). 15 However, some advocate for an individualized approach, with stringent HbA1c goals (6.0%-6.5%) in selected healthy subjects and a relaxed goal (7.5%-8%) in those with health complications and those without sufficient empowerment, resources or social support. 10, 11, 13, 14 Regarding the appropriate interval to medication adjustment, some recommend intensifying therapy whenever HbA1c exceeds the individualized target, and others when the patient is not maintained at his/her target for an interval of 3 months. [10] [11] [12] Literature reviews investigating patterns of antidiabetic treatment related to initiation and intensification of both non-insulin antidiabetic drugs (NIADs) and insulin therapy in real-world settings have documented therapeutic inertia as a factor contributing to suboptimal glycaemic management globally. 2, 16 Of note, all studies reported that HbA1c levels far exceed acceptable thresholds at the time of treatment intensification, regardless of the sequential therapeutic step considered. 2, 16 In Spain, studies conducted in primary healthcare services reported that the lack of intensification in patients with poor glycaemic control (HbA1c ≥ 7%) varies between 32.2% and 52.5%. [17] [18] [19] The longest delays in treatment intensification are known to occur among patients receiving 2 or more NIADs. 2, 16 On the one hand, for patients with glycaemic levels between 7% and 8%, the term "therapeutic inertia" may not always apply if it is more appropriate not to intensify, based on established individualized targets and to avoid overtreatment. 10, 11, 20 On the other hand, patients with glycaemic levels ≥8% are those most likely to benefit from timely intensification in order to avoid sustained hyperglycaemia. Most studies assessing real-life patterns of treatment intensification in diabetes have been conducted in the USA and the UK, 2, 16 with a marked absence of studies covering regions in the Mediterranean area. The aim of the present study was to evaluate real-life patterns of treatment intensification beyond 2 concurrent NIADS in patients with T2DM in primary care in Catalonia (Spain). Our aims were to determine the frequency of intensification at the end of the follow-up period, the duration of time to therapy intensification, and the factors associated with the likelihood of medication escalation.
| RESEARCH DESIGN AND METHODS

| Study design and data source
This was a retrospective, cohort study using the SIDIAP (System for 
| Statistical methods
Continuous variables were summarized using mean and standard GLP-1RA was not grouped together with insulin as "injectable therapies" because local guidelines recommend them only when intensification is not possible with insulin, and because its use in our health region is very low (0.9% of patients). 14, 24 Time to first treatment intensification with any new antidiabetic treatment, any new NIAD and insulin was evaluated by time-to-event analysis with a competing-risks regression using the method of Fine and Gray, 25 
| RESULTS
Among the 301 144 patients with T2DM registered in the database on January 1, 2010, a total of 23 678 patients treated with ≥2 concurrent NIADs and with HbA1c values ≥7% were included in the study ( Figure S1 , Appendix S1 
| Treatment intensification in the overall cohort
Among the overall cohort (patients with HbA1c ≥ 7% at baseline), 73.8% received treatment intensification, while 26.2% (n = 6213)
were censored without any drug escalation (Table 1 and Figure S3 , Appendix S1). The mean HbA1c value at baseline among intensified patients was 8.6%, and 8.0% among those not intensified (Table 1 and Figure S4 , Appendix S1). Most of the intensified patients (59.8%)
had an HbA1c value ≥8%, while the majority of not-intensified patients (63%) had an HbA1c value <8% (Table 1) . By glycaemic subgroup, the highest proportion of not-intensified patients had a baseline HbA1c between 7.0% and 7.9% (35.8%), and this percentage decreased to 19.8% and 11.5% in the 2 subgroups with higher levels (8.0%-9.9% and ≥10%, respectively) ( Figure S3 , Appendix S1) (P < .001).
| Therapeutic inertia in patients with
HbA1c > 8% at baseline or during follow-up
In the subgroup of patients with HbA1c values ≥8% at baseline or during follow-up (n = 12 730), treatment was not intensified (therapeutic inertia) in 18.1% of cases (n = 2299) ( Figure S5 , Appendix S1), and they had a mean HbA1c value of 8.7% (AE0.97), while those who were intensified had a mean value of 9.0% (AE1.16) ( Figure S4 , Appendix S1).
| HbA1c levels prior to intensification
The mean HbA1c value prior to any treatment escalation was 9.0% (AE1.4), 8.7% (AE1.3) before the first added NIAD and 9.4% (AE1.5)
among those who were intensified with insulin ( Figure S4 , Appendix S1). In the subgroup of patients with HbA1c levels ≥8% at baseline or at any time during the study period, the mean value prior to any treatment intensification was 9.4% (AE1.24), 9.2% (AE1.1) before the first added NIAD and 9.7% (AE1.3) among those who received insulin ( Figure S4 , Appendix S1). Based on HbA1c categories prior to treatment intensification, a new NIAD was the most frequent addition among patients with HbA1c levels 7.0% to 7.9% (69.3%), either a new NIAD or insulin among patients with 8.0% to 9.9% levels (50.8% and 49.2%, respectively), and insulin among patients with ≥10% levels (66.3%).
| Time to treatment intensification
In the overall population, the median time to first intensification (addition of any new antidiabetic agent regardless of type, ie, an NIAD or insulin) was 22.6 months (IQR, 6.9-59.9), and less with progressive increase in HbA1c levels ( Table 2 and Figure 1A ): from HbA1c ≥ 10%. Similarly, the probability of intensification at the end of follow-up was 73.8%; this increased in parallel with the increase in HbA1c levels, from 64.3% when HbA1c was 7.9% to 7.9% to 88.5% among those with levels ≥10%.
Among all intensified patients, the relative proportion that was intensified with a new NIAD as the first change to the index regimen was higher than the proportion that received insulin as the first change (63.8% vs 36.2%) ( Table 2 ). However, the probability of receiving insulin increased gradually and in parallel with the increase in HbA1c levels ( Table 2 and Figure 1B and C). For instance, 30.5%
of patients with HbA1c levels 7.0% to 7.99% received insulin as the first change (19.6% probability), but this increased up to 49.9% (43.4% probability) when HbA1c levels were ≥10%.
| Factors predicting intensification
Covariate analysis showed that the probability of having treatment Table S1 , Appendix S1). Conversely, covariates associated with a higher probability of treatment intensification were 
| DISCUSSION
This population-based retrospective analysis of adult patients with T2DM concomitantly treated with ≥2 NIADs showed that 26.2% of patients with a baseline HbA1c level ≥7% were not intensified during 5 years of follow-up, and therapeutic inertia was present in up to 18% of patients with HbA1c levels ≥8%. Therapy escalation occurred following a significant deterioration in glycaemic levels, and it was delayed far beyond the 3 to 6 months typically advocated by clinical guidelines. Finally, the transition to new treatment regimens was least frequent among older patients and those with complex regimens, and occurred most frequently among those with HbA1c levels >8% and those with long-standing disease, kidney disease or high comorbidity.
The baseline demographic characteristics of our study population, with a mean age above 65 years, more than half of the patients with mean HbA1c levels at baseline ≥8.0% and long-standing diabetes (mean of 8 years), largely reflect an advanced disease that progressively decreased the probability of maintaining adequate glycaemic control over time. Treatment was not intensified in 26.2%
patients with HbA1c baseline values ≥7%, and the majority of patients who remained in the same index regimen had glycaemic levels between 7% and 7.9%. This could indicate that an HbA1c value <8%, considered as the threshold to avoid overtreatment in the elderly, as incentivization in our health care setting, 15 and also the superior limit for individualized goals advocated by some clinical guidelines, 11, 14, 26 is being implemented in part. Nonetheless, in patients with evident inadequate glycaemic control ≥8%, therapeutic inertia was present in 18.1% of cases, which is lower than that found in previous studies. [27] [28] [29] [30] The largest retrospective study published to date, conducted in >80 000 patients in the UK, reported that the probability of treatment intensification in patients receiving 2 or 3 oral antidiabetic drugs (OADs) at the end of a 7-year follow-up period was <50%, regardless of the cut-off considered (≥7.0, ≥7.5% or ≥8%). 27 Our figures support previous findings from the few additional studies providing data on the subgroup of patients receiving ≥2
OADs, with clinical inertia values of 34.5% when poor glycaemic control was defined as an HbA1c value >7%, 18 between 18% and 51.3% when set to 8%, [28] [29] [30] and 53.1% with a 9% cut-off. 31 Variability among studies may be attributable to several factors, including type of health care setting (primary care, secondary care, private or public), duration of diabetes, treatment revision type (eg, OAD used for the first time, new OAD addition, switch to insulin, or all) and duration of the observational period. Last, but not least, it is also important to know if dose escalation was considered as a form of intensification, as prescribing an increased dose is more likely to take place among adherent patients still not reaching glycaemic targets compared with those who are not adherent; 32 thus, therapeutic inertia may have been overestimated.
The mean HbA1c value prior to any treatment intensification was 9.0% in the overall population, and was higher ( The median time spent before previous treatment was escalated with a new NIAD or insulin was far longer than the recommended 3 to 6 months for patients not meeting glycaemic targets before therapy is intensified. 11, 12, 14, 37 Our results are in line with previous studies reporting large delays in therapy escalation among patients receiving ≥2 OADs, and also reporting that the time lag is shorter among patients with the most poorly controlled glycaemic levels BMI, body mass index; eGFR, estimated glomerular fraction; HbA1c, glycated hemoglobin; HF, heart failure; NIAD, non-insulin antidiabetic; aSHR, adjusted subhazard ratio (95%C) FIGURE 2 Adjusted subhazard ratios according to regression competing risk model for factors associated with likelihood of treatment intensification (>7 years in patients with levels ≥7%, 27,33 and 4.9 to >7 years in patients with levels ≥8%). Strengths of our study include the large sample size and the fact that it was conducted in a real-world setting that reflects routine clinical practice. However, the results of our study should be interpreted with potential limitations in mind. This was a retrospective analysis, intrinsically subject to incomplete documentation and loss of data concerning some of the studied variables; however, to minimize this limitation, subjects without basal HbA1c values or less than 1 year of follow-up were excluded. Furthermore, the study was conducted in an area that may not be completely representative of other areas inside or outside Spain, with different health care systems or prescription policies. Moreover, the censored nature of the study might have underestimated intensification times, although lack of intensification might be explained by sound reasons other than insufficient follow-up duration; for instance, a less stringent individualized approach was chosen, or other factors were taken into consideration, such as medication cost, inadequate patient adherence or risk of secondary effects. Also, although patients do not have financial barriers to adequate care, because they are treated at centres within the public healthcare system, the pay-per-performance model of our institution advises against the use of drug classes other than metformin, sulphonylureas or insulin, and prescription of the newest (and more expensive) drugs entails negative economic incentives for the physicians. In addition, we did not consider a dose increase within the same drug class as a form of therapy intensification, and intensification was defined as only an add-on, which precludes the distinction of an actual intensification from a treatment switch, all of which might have led to an overestimation of therapeutic inertia. Similarly, we considered fixed-dose combinations as 2 different NIADs, but they have been reported to be associated with greater adherence compared to the combination of separate pills, 55 which may impact the need for treatment intensification in some cases. Moreover, differences between general practitioners and endocrinologists must be taken into account, as specialists are more likely to use insulin therapies (eg, in 8.6% and 1.7%, respectively, of patients with poor glycaemic control) 16 and they tend to initiate insulin treatment sooner than primary care physicians. 56 This probably reflects a referral bias, with specialists managing the most advanced and complex patients and, hence, those with the worst glycaemic control. Nevertheless, the SIDIAP database includes prescriptions from both specialists and primary care physicians, with no differentiation of origin. Finally, we did not have information concerning patient-related personal factors (eg, socio-economic status, level of education, urban vs rural location, or marital status), concerning organizational or structural differences among health care centres (eg, working conditions or lack of teambased care), 20 drug dose escalations or additional predictors of a higher chance of treatment intensification, such as good adherence to treatment, 28, 32, 41, 45 more frequent and recent outpatient visits, 30, 41, 44 specialist visits, 49, 51, 57 high doses of OADs at baseline, 28, 44 or use of concomitant medications. 41, 44 In conclusion, the primary findings of this retrospective study showed that lack of treatment intensification was present in 1 in 5 patients with HbA1c values >8% at baseline, and that the time to introduction of a new NIAD or insulin exceeded that recommended before therapy is intensified. Overcoming therapeutic inertia should be an important goal for healthcare providers in the management of T2DM, and it could be minimized through more intense training and education or the development of practice-based interventions aimed at promoting early and well-timed medication adjustments.
